Products
Siltuximab was approved in many countries in 2014 as a powder for a concentrate for [infusion solution>infusion] (Sylvant).
Structure and properties
Siltuximab is a human murine chimeric monoclonal antibody that binds human interleukin-6 (IL-6).
Effects
Siltuximab (ATC L04AC11) has anti-inflammatory and immunosuppressive properties. It prevents binding of human interleukin-6 to IL-6 receptors.
Indications
For the treatment of adult patients with multicentric Castleman disease who are HIV-negative and HHV-8-negative.
Dosage
According to the SmPC. The drug is administered as an intravenous infusion.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Adverse effects
The most common possible adverse effects include infection, pruritus, and maculopapular rash.
